Regeneron Pharmaceuticals Inc (REGN)vsWoodside Energy Group Ltd (WDS)
REGN
Regeneron Pharmaceuticals Inc
$714.89
+0.82%
HEALTHCARE · Cap: $74.34B
WDS
Woodside Energy Group Ltd
$21.57
-1.55%
ENERGY · Cap: $43.23B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 15% more annual revenue ($14.92B vs $12.98B). REGN leads profitability with a 29.6% profit margin vs 20.9%. WDS appears more attractively valued with a PEG of 1.33. REGN earns a higher WallStSmart Score of 64/100 (C+).
REGN
Buy64
out of 100
Grade: C+
WDS
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+50.8%
Fair Value
$1452.32
Current Price
$714.89
$737.43 discount
Margin of Safety
+31.5%
Fair Value
$27.39
Current Price
$21.57
$5.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 20.7%
Reasonable price relative to book value
Keeps 21 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
Weak financial health signals
Earnings declined 7.2%
ROE of 7.2% — below average capital efficiency
Weak financial health signals
Revenue declined 11.1%
Earnings declined 14.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : REGN
The strongest argument for REGN centers on Altman Z-Score, Market Cap, Profit Margin. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bull Case : WDS
The strongest argument for WDS centers on Price/Book, Profit Margin, P/E Ratio. Profitability is solid with margins at 20.9% and operating margin at 19.1%. PEG of 1.33 suggests the stock is reasonably priced for its growth.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Bear Case : WDS
The primary concerns for WDS are Return on Equity, Piotroski F-Score, Revenue Growth.
Key Dynamics to Monitor
REGN profiles as a growth stock while WDS is a declining play — different risk/reward profiles.
REGN carries more volatility with a beta of 0.30 — expect wider price swings.
REGN is growing revenue faster at 19.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 53/100), backed by strong 29.6% margins and 19.0% revenue growth. WDS offers better value entry with a 31.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Woodside Energy Group Ltd
ENERGY · OIL & GAS E&P · USA
Woodside Energy Group Ltd is engaged in the exploration, evaluation, development, production, marketing and sale of hydrocarbons in Oceania, Asia, Canada, Africa and internationally. The company is headquartered in Perth, Australia.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?